Sensei Biotherapeutics Inc - Asset Resilience Ratio
Sensei Biotherapeutics Inc (SNSE) has an Asset Resilience Ratio of 24.57% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sensei Biotherapeutics Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Sensei Biotherapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Sensei Biotherapeutics Inc assets under control.
Liquid Assets Composition Over Time
This chart breaks down Sensei Biotherapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Sensei Biotherapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $50.47 Million | 24.57% |
| Total Liquid Assets | $50.47 Million | 24.57% |
Asset Resilience Insights
- Good Liquidity Position: Sensei Biotherapeutics Inc maintains a healthy 24.57% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Sensei Biotherapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Sensei Biotherapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Sensei Biotherapeutics Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Sensei Biotherapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 54.65% | $12.52 Million | $22.90 Million | -14.44pp |
| 2024-12-31 | 69.09% | $31.34 Million | $45.36 Million | -1.83pp |
| 2023-12-31 | 70.92% | $52.75 Million | $74.37 Million | -4.54pp |
| 2022-12-31 | 75.46% | $89.32 Million | $118.38 Million | -16.21pp |
| 2021-12-31 | 91.67% | $140.46 Million | $153.22 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $21.43 Million | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune … Read more